AdaptHealth earnings and impairment move into focus

AdaptHealth (AHCO) is back on investors’ radar after second quarter 2026 results showed a net loss alongside a sizeable goodwill impairment, while management also updated full year revenue guidance.

The company reported quarterly sales of US$740.31 million and a net loss of US$133.93 million, compared with net income a year earlier. It also recorded an unaudited goodwill impairment charge of US$144.24 million.

Alongside these results, AdaptHealth issued revised guidance for fiscal 2026, with expected net revenue in a range of US$2.85 billion to US$2.89 billion. This combination of loss-making results and updated outlook is drawing renewed attention to the stock today.

The earnings release and goodwill impairment have coincided with sharp share price pressure for AdaptHealth, with the stock closing at US$5.69 after a 1 day share price return of down 5.87% and a 7 day share price return of down 47.31%. Over longer periods, the 1 year total shareholder return is down 38.08% and the 5 year total shareholder return is down 77.35%, which signals that recent weakness is part of a longer period where momentum has been fading.

If this kind of volatility has you reassessing your watchlist, it can help to compare AdaptHealth with other healthcare focused opportunities that use AI driven tools. Start by scanning the 43 healthcare AI stocks

Bulls point to AdaptHealth’s revenue base and value score, while bears focus on the fresh loss and goodwill hit after a steep share slide. Which side does the current valuation lean toward?

Most Popular Narrative: 43.1% Undervalued

AdaptHealth’s most followed narrative pegs fair value at $10 per share, which sits well above the last close at $5.69 and frames the latest volatility in a different light.

While AdaptHealth is well positioned to benefit from the aging population and growing demand for home healthcare thanks to its new large-scale, multi-year capitated contract that brings over $1 billion of locked-in revenue, the company faces significant near-term headwinds as the infrastructure investments needed to support this deal will sharply increase operating expenses and capital expenditures, which could suppress free cash flow and pressure net margins through 2026.

Want to understand why this AdaptHealth view still points to upside despite expected revenue contraction? The heart of the narrative is how margin repair, contract economics and a re-rated earnings multiple intersect. The detailed model blends changing revenue mix, forecast profitability and discount rate shifts into one fair value line. The interesting part is which assumption really does the heavy lifting.

Result: Fair Value of $10 (UNDERVALUED)

However, this AdaptHealth narrative can quickly shift if CMS reimbursement cuts or execution issues on the new capitated contract put additional pressure on margins and cash flow.

Next Steps

The mix of concern and optimism around AdaptHealth is clear. It is worth checking the underlying data directly and moving quickly to form your own view based on the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond AdaptHealth?

If you only stick with AdaptHealth, you may miss other opportunities that fit your goals. Spend a few minutes with these ideas before your next move.

• Spot potential turnaround opportunities early by scanning 20 elite penny stocks with strong financials that pair smaller market caps with stronger financial profiles than many peers.
• Zero in on quality at a reasonable price by reviewing the 51 high quality undervalued stocks that combine solid cash flows with supportive balance sheets.
• Build a more defensive core by checking the 79 resilient stocks with low risk scores that aim for resilience when markets become choppy.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.